A paper published in Pharmaceutics describes development and validation of a production process for 5 mg tablets of infliximab, using biosimilar CT-P13 (Remsima, Inflectra), for the treatment of inflammatory bowel disease.
The oral delivery of biologic drugs represents an as-yet unattained goal. However, the potential benefits of oral administration of these therapies in terms of compliance, comfort, and drug storage are many, and several drug makers are pursuing the possibility: Last year, Amgen and Entera Bio announced a research collaboration into oral administration of biologics, and Protalix BioTherapeutics announced positive results from a study on oral administration of anti—tumor necrosis factor (anti-TNF) therapies.
Now, a paper published in Pharmaceutics describes development and validation of a production process for 5 mg tablets of infliximab, using biosimilar CT-P13 (Remsima, Inflectra), for the treatment of inflammatory bowel disease (IBD).
The authors of the paper hypothesized that, in IBD, targeting infliximab administration to the ileo-colonic region could be efficacious in treating local IBD inflammation.
The researchers used the biosimilar infliximab and reconstituted it into a sugar solution that, when lyophilized, yielded powder that could be further compounded and treated with a coating.
The coating technology (called ColoPulse) used on the tablets has a pH sensitive polymer; the intraluminal pH of the gastrointestinal tract rises during transit from the jejunum to the ileum, then drops in the colon, and the tablet’s coating uses this period of pH increase to disintegrate in the terminal ileum.
According to the researchers, the in vitro stability of infliximab in simulated gastrointestinal systems is “encouraging,” and analyses of infliximab content, tertiary protein structure, aggregates, and potency showed that the infliximab present in the coated tablet was stable during compounding and could bind to TNF.
Stability data showed that the preparation was stable for up to 6 months at 25°C.
The authors note that a clinical trial will be necessary to determine the such factors as the pharmacokinetics of the proposed coated tablet, as well as the potential for development of anti-drug antibodies.
Reference
Gareb B, Posthumus S, Beugeling M, et al. Towards the oral treatment of ileo-colonic inflammatory bowel disease with infliximab tablets: development and validation of the production process. Pharmaceutics. 2019;11(9):428. doi: 10.3390/pharmaceutics11090428.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Phase 3 Trials Find Subcutaneous Infliximab CT-P13 Superior to Placebo in IBD
June 29th 2024Two phase 3 trials in patients with inflammatory bowel disease (IBD) found higher clinical remission rates in those treated with the subcutaneous formulation of infliximab biosimilar CT-P13 compared with placebo as maintenance therapy following an induction phase of intravenous CT-P13.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.